Accumulating evidence suggests that hepatitis E virus (HEV) infection is an emerging disease in regions
where HEV is nonendemic. In France, the prevalence of anti-HEV antibodies in the general population has never been studied. Using blood donors' samples, we have found a prevalence of 3.20%, which is similar to that of other industrialized countries.
Hepatitis E virus (HEV) is responsible for acute hepatitis in humans and associated with large waterborne epidemics in Asia and Africa, where it is endemic (3) . To a lesser extent, HEV infection leads, in 1 to 2% of cases, to lethal fulminating hepatitis, and this level reaches 20% in pregnant women infected during their third term in areas of endemicity (8) . In the industrialized countries of the United States, Europe, and Japan, HEV is responsible for sporadic cases, and genotyping combined with phylogenetic analysis has shown that the origin of these cases is mostly autochthonous, thus suggesting that the virus is present locally (1) . In Europe (The Netherlands, the United Kingdom, Spain, Italy, and Sweden), the prevalence of anti-HEV antibodies ranges from 2.20 to 9.30% (2, 5, 6, 10) . In France, the National Reference Centre reports 40 to 60 autochthonous cases every year, but the prevalence of HEV is not yet known. HEV serology or detection is not systematically performed in cases of acute hepatitis, even if HAV or HBV infection is ruled out. HEV is still considered an imported disease from regions of endemicity, and without a recent history of travel in these regions, a diagnosis of HEV infection is made only occasionally. In the southern part of France, acute hepatitis associated with HEV infection seems to be becoming more frequent than that due to HAV, suggesting that HEV is an emerging virus (7) .
In contrast to regions of endemicity where the water vector has been well characterized, very little is known about the mode of transmission in regions where HEV is nonendemic. Unlike the other hepatitis viruses, HEV has animal reservoirs. Several lines of evidence, such as phylogenetic analysis and direct contamination through infected food products (wild boar or deer) (4, 9) , have shown that animal-to-human transmission occurs and that HEV is in some cases a zoonotic virus. Among risk factors associated with hepatitis E, contact with swine seems to increase HEV prevalence. In the United States and Sweden, studies on HEV prevalence among swine handlers and veterinarian workers have shown higher prevalences in these populations (13% versus 9.3% for control subjects in Sweden) (5, 6) .
To determine whether hepatitis E is a frequent disease in France and to establish a starting point for further studies on HEV epidemiology, HEV prevalence was estimated in the general population using sera from blood donors from two regions of France. The first region, Ile de France, is located near Paris, in an urban area, and the second one, Pays de Loire, is located in the west of France, in a rural area with many swine herds.
Sera from 998 blood donors from Ile de France and 1,000 sera from Pays de Loire were obtained from the Établissement Française du Sang. Information on sex, age, and travel to regions of HEV endemicity were provided.
Prevalence of anti-HEV antibodies (immunoglobulin G [IgG]) was determined by an HEV enzyme-linked immunosorbent in Pays de Loire. The prevalence in male subjects was similar to that in female subjects, at 3.14%, but a slightly higher prevalence was observed among males from Pays de Loire (3.72%) than in males from Ile de France (2.42%), suggesting that exposure to HEV might be more frequent in this region. No data on work activities of the donors were available, but it would be interesting to know whether some of them had occupations related to swineherds. Another possibility is that sanitation may play a more prominent role in urban than rural areas. None of the positive donors had a recent history of travel in regions of endemicity, but the possibility that they had traveled outside France a long time ago and been exposed to HEV cannot be excluded. Thus, it is not possible to conclude that HEV was acquired locally. Hepatitis E is observed in young adults in regions of endemicity, but in industrialized countries, HEV seems to be more frequent in older adults. To characterize this epidemiological feature of HEV infection in France, the data of four age groups were analyzed: Յ24, 25 to 34, 35 to 44, and Ն45 years of age. Globally, HEV prevalence was higher (5.17%) in people who were Ն45 years of age, regardless of their geographical region of origin (4.60% in Ile de France and 5.42% in Pays de Loire) or gender (female, 5.11%; male, 5.22%) ( Table 2) . Thus, the probability of being exposed to HEV seems to increase with age. However, the possibility cannot be totally excluded that many years ago HEV infection was more prevalent than it is today and as a result the group of subjects who were Ն45 years of age had the highest prevalence. While prevalence was heterogeneous in the 35-to 44-year-old age group in the two regions (from 0 to 5.21%), the prevalence in female subjects was higher than that in males, without any particular epidemiological factor that could explain why females might be more frequently exposed than men. In the 25-to 34-year-old age group, some variability was also observed, with the highest prevalence found in male subjects from Pays de Loire (4.95%). Along the same line, male subjects from Pays de Loire may have occupations involving swine and, thus, might be more frequently exposed.
In young adults (Յ24 years old) from the two regions, prevalences ranged between 1.49% and 3.06%. These low values underscore that HEV epidemiology in regions of nonendemicity is fundamentally different from that in regions of endemicity. Young women do not demonstrate any increased risk for HEV infection, thus limiting the risk of major liver failure during pregnancy.
In conclusion, these first data collected in France indicate that the HEV seroprevalence is similar to that of other European countries. These data constitute a starting point in HEV surveillance and will help to determine whether HEV is an emerging disease and needs increased attention. These data also underscore that both male and female subjects over 45 years of age have a higher risk of exposure to HEV. Women between 35 and 44 years of age are also more frequently exposed than men of the same age. An extended study on these populations with a detailed questionnaire may contribute to the identification of risk factors associated with HEV infection and the identification of transmission pathways in regions where HEV is nonendemic. 
